Cumberland, Rhode Island | June 02, 2020 | TEDOR Pharma is pleased to announce they have agreed to work with Cardinal Health Regulatory Sciences to deliver integrated solutions to the biopharmaceutical industry. These solutions would leverage the regulatory consulting expertise of Cardinal Health and TEDOR’s world class oral solid dose manufacturing capabilities and exclusive North American drug delivery technologies.
Under the business agreement, TEDOR Pharma will be able to provide its best-in-class technology and will work collaboratively with Cardinal Health to deliver integrated regulatory solutions to meet the needs of the evolving manufacturing compliance environment. The agreement will provide effective solutions that reflect TEDOR’s customer service commitment to deliver significant value to clients and shareholders.
“Bringing together the deep industry expertise of Cardinal Health Regulatory Sciences with TEDOR’s collaborative approach in contract development and manufacturing will be transformative for our clients,” said Doug Drysdale, President and Chief Executive Officer of TEDOR. “Working together will drive new solutions and redefine how we meet the business needs of the market.”
About TEDOR Pharma, Inc.
Founded in 2001, TEDOR Pharma is a specialized Contract Development and Manufacturing Organization with a strong track record of success in providing development and manufacturing services for oral solid dose products, including DEA-scheduled products, for life science customers. Over nearly two decades, TEDOR has helped customers meet their project timelines, achieve regulatory approvals, and solve formulation challenges. TEDOR offers services ranging from formulation development, clinical trial manufacturing, scale-up and full-scale commercial manufacturing, tech transfer, stability studies, and product life cycle management with patented FLEXITAB™ technology.